|
Neximmune Inc
NEXI's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Neximmune Inc 's sales fell
in the second quarter of 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 5.18 %
Neximmune Inc net loss decreased from $-8 millions, to $-2 millions in second quarter of 2024,
• More on NEXI's Growth
|
|
Neximmune Inc realized a net loss in trailing twelve months.
Neximmune Inc realized cash reduction of $ -10.06 per share in trailing twelve-month period. |
Company |
-0 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.44.
• More on NEXI's Valuation
|
|
|
|
|
Neximmune Inc realized net loss in trailing twelve months.
Neximmune Inc realized cash outflow of $ -10.06per share in trailing twelve-month period. |
Company |
-0 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.44.
Neximmune Inc Price to Book Ratio is at 0 lower than Industry Avg. of 34.79. and lower than S&P 500 Avg. of 0.01
• More on NEXI's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com